How Mammoth Biosciences Is Advancing Gene Editing With Ultracompact CRISPR Technology

The landscape of genetic medicine is shifting from "searching and snipping" to providing permanent, durable cures for complex diseases. At the forefront of this transition is Mammoth Biosciences, a company that has moved beyond the initial excitement of the CRISPR-Cas9 era to develop what they call the "next generation" of gene editing tools. Founded in 2017 by Jennifer Doudna, Trevor Martin, Janice Chen, and Lucas Harrington, the company is built on the premise that the diversity of the CRISPR universe is far greater than the industry-standard Cas9 enzyme.

By exploring the vast microbial world, Mammoth has identified and engineered enzymes that are not only more precise but also significantly smaller than their predecessors. This technical advantage addresses the "cargo problem"—the physical limitation of how much genetic material can be packed into a delivery vehicle—which has long been a bottleneck for in vivo gene editing. As we look at the company's status in 2026, it is clear that their strategic focus on therapeutics and high-value partnerships has positioned them as a top choice for investors and researchers alike.

What Makes the Mammoth Biosciences Platform Different From Legacy CRISPR?

To understand Mammoth's value proposition, one must look at the diversity of their enzyme library. While most early CRISPR companies focused exclusively on Cas9, Mammoth has built a platform around Cas12, Cas13, Cas14, and CasΦ (Cas-Phi). Each of these enzymes offers unique properties that make them suitable for different applications. For instance, Cas13 is designed to target RNA rather than DNA, offering a temporary way to modulate gene expression without making permanent changes to the genome.

However, the real standout in their portfolio is the ultracompact CRISPR systems. According to Wikipedia's overview of the company, Mammoth's discovery of Cas14 and CasΦ represented a significant step forward in the field. These enzymes are derived from bacteriophages (viruses that infect bacteria) and are remarkably small compared to the Cas9 found in Streptococcus pyogenes. This size difference is not just a biological curiosity; it is a fundamental engineering advantage that enables new types of treatments that were previously impossible.

Why Size Matters for the Future of In Vivo Gene Editing

In the world of gene therapy, the "cargo problem" refers to the capacity limits of delivery vehicles, most notably Adeno-associated viruses (AAV). AAVs are widely regarded as one of the safest and most effective ways to deliver genetic material into human cells, but they have a strict capacity limit of approximately 4.7 kilobases (kb). Standard Cas9, along with the necessary guide RNAs and promoter sequences, often pushes this limit to the breaking point.

When a CRISPR system is too large, researchers are forced to use "split-AAV" systems, where the components are delivered by two separate viruses that must both enter the same cell to work. This increases the complexity of the treatment, raises the cost of manufacturing, and potentially increases the risk of an immune response. Mammoth’s ultracompact enzymes solve this by enabling "all-in-one" AAV delivery. By fitting the entire editing machinery into a single viral vehicle, Mammoth can achieve higher efficiency with a lower dose of the virus.

This technical edge is particularly relevant for treating diseases in tissues that are difficult to reach, such as the central nervous system (CNS) and muscle tissue. While Lipid Nanoparticles (LNPs) are excellent for delivering CRISPR to the liver, AAV remains a top-tier option for extrahepatic (outside the liver) targets. Mammoth’s ability to utilize AAV more efficiently than its competitors sets a high standard for the next wave of in vivo therapies.

The 2023 Strategic Pivot From Diagnostics to Therapeutics

In 2023, Mammoth Biosciences underwent a significant restructuring that signaled a shift in its long-term vision. During the COVID-19 pandemic, the company gained widespread attention for its DETECTR platform, a CRISPR-based diagnostic tool that could identify viral RNA with high sensitivity. However, as the global health landscape changed, the company made the difficult decision to scale back its diagnostics division, resulting in the layoff of approximately 35 employees.

This pivot was not a sign of weakness, but rather a strategic realignment toward the much larger and more lucrative therapeutics market. By focusing on in vivo gene editing, Mammoth is moving toward developing permanent cures for genetic diseases rather than just tools for detection. This shift has allowed the company to concentrate its R&D resources on its most promising therapeutic candidates and secure high-value partnerships with established pharmaceutical giants.

• 2017-2019: Foundation & Discovery - Co-founded by Jennifer Doudna; discovery of Cas14 and CasΦ enzymes.
• 2020-2022: Diagnostic Expansion - Development of the DETECTR platform; emergency use authorizations for COVID-19 testing.
• 2023: The Strategic Pivot - Restructuring to focus exclusively on therapeutics; scaling back diagnostic operations.
• 2024-2026: Clinical Acceleration - Series D funding; major collaboration with Regeneron; advancement of MB-111.

A Deep Dive Into the Mammoth Biosciences Therapeutic Pipeline

How MB-111 Targets Liver Disease via APOC3 Inactivation

The lead candidate in Mammoth’s pipeline is MB-111, an in vivo gene editing therapy designed to treat Familial Chylomicronemia Syndrome (FCS) and severe hypertriglyceridemia. These conditions are characterized by dangerously high levels of triglycerides in the blood, which can lead to life-threatening pancreatitis. MB-111 works by using CRISPR to permanently inactivate the APOC3 gene in the liver.

According to Mammoth’s official therapeutics roadmap, MB-111 utilizes Lipid Nanoparticle (LNP) delivery, which is a proven method for reaching liver cells. By knocking out the APOC3 gene, the therapy aims to reduce the production of proteins that inhibit the breakdown of fats, thereby lowering triglyceride levels with a single treatment. This "one-and-done" approach represents a significant advancement over current treatments that require lifelong medication.

Expanding Into CNS and Neuromuscular Targets

Beyond the liver, Mammoth is leveraging its ultracompact enzymes to target the Central Nervous System (CNS) and neuromuscular diseases. These areas have traditionally been difficult for CRISPR because of the delivery challenges mentioned earlier. Because CasΦ and Cas14 can fit into a single AAV, Mammoth can potentially treat genetic disorders of the brain and muscles more effectively than companies using larger Cas9 systems. While many of these programs remain in the discovery or lead optimization phase, they represent the future growth engine of the company.

The Abu Dhabi Connection and Global Research Expansion

In a notably innovative move, Mammoth recently signed a tripartite Memorandum of Understanding (MoU) with the Abu Dhabi Department of Health and M42 Health. This partnership aims to integrate Mammoth’s gene editing technology into Abu Dhabi’s world-class healthcare ecosystem. By leveraging one of the world’s largest population genomics datasets, Mammoth can accelerate the clinical development of MB-111 and other pipeline candidates. This global expansion provides the company with access to diverse patient populations and high-quality genomic data that is essential for refining their editing tools.

Strategic Partnerships With Regeneron and Vertex Pharmaceuticals

Breaking Down the 100 Million Dollar Regeneron Collaboration

One of the most significant milestones for Mammoth in recent years was the 2024 announcement of a broad collaboration with Regeneron Pharmaceuticals. The deal included a $95 million equity investment and a $5 million upfront payment, signaling Regeneron’s long-term confidence in Mammoth’s platform. Unlike many biotech deals that are purely project-based, this equity stake suggests a deep strategic alignment between the two companies.

Under the terms of the agreement, the companies will work together to develop in vivo therapies for a variety of targets. Mammoth is eligible to receive up to $370 million in milestone payments per target, plus royalties on future sales. A unique feature of this deal is Mammoth’s "opt-in" right to share in the profits and losses of certain programs, a provision that is typically reserved for more mature biotech firms. This allows Mammoth to capture more of the long-term value of their discoveries rather than just acting as a service provider.

Collaborative Efforts With Vertex and Bayer

Regeneron is not the only major player interested in Mammoth’s tech. The company also has an ongoing collaboration with Vertex Pharmaceuticals, a leader in the treatment of cystic fibrosis and sickle cell disease. According to Vertex's press release, the partnership focuses on using Mammoth’s ultracompact CRISPR tools to develop therapies for undisclosed diseases. Additionally, a prior deal with Bayer highlighted the potential for Mammoth’s platform to be used in a wide range of therapeutic areas, further validating the versatility of their enzyme library.

Is Mammoth Biosciences Publicly Traded?

As of September 2026, Mammoth Biosciences remains a private company. It is currently classified as a "Unicorn," a startup valued at over $1 billion. While there is significant interest from retail investors in a "Mammoth Biosciences stock," the company has not yet filed for an Initial Public Offering (IPO). Instead, it has continued to raise capital through private funding rounds, including a successful Series D round that raised $107 million in April 2024.

For those looking to invest, the primary options are secondary markets such as Linqto, Forge Global, or EquityZen, which allow accredited investors to buy shares from early employees or venture capital firms. According to data from the Nasdaq Private Market, recent estimates suggest a share price of approximately $7.48, though these figures can fluctuate based on market demand and company milestones. Investors should note that private biotech investments carry high risk, as the company's valuation is heavily dependent on clinical trial outcomes that have not yet been fully realized.

What Is It Like to Work at Mammoth Biosciences?

For prospective employees, Mammoth Biosciences offers the opportunity to work at the cutting edge of genomic medicine. The company is led by a highly respected management team, including CEO Trevor Martin and CTO Janice Chen. Reviews on platforms like Glassdoor and BuiltIn generally describe a culture of high scientific rigor and innovation. Employees often cite the opportunity to work with Nobel-caliber scientists as a primary draw.

However, like many high-growth biotech firms, the environment can be intense. The 2023 pivot and subsequent layoffs served as a reminder of the volatility inherent in the startup world. Since then, the company has focused on building a more stable, therapeutics-centered organization. Job seekers with expertise in molecular biology, bioinformatics, and clinical development will find Mammoth to be a leading choice for career growth, provided they are comfortable with the fast-paced nature of a private biotech firm.

Frequently Asked Questions

Who owns Mammoth Biosciences?

Mammoth is a privately held company owned by its founders (Jennifer Doudna, Trevor Martin, Janice Chen, Lucas Harrington), venture capital firms like 8VC and Mayfield, and strategic partners like Regeneron. Individual investors like Tim Cook also hold stakes in the company.

Is Jennifer Doudna still involved with Mammoth Biosciences?

Yes, Jennifer Doudna remains a co-founder and a member of the Board of Directors. Her scientific leadership and the intellectual property generated by her lab at UC Berkeley continue to be foundational to the company’s platform.

What is the difference between Cas9 and Mammoth’s Cas proteins?

The primary difference is size and delivery efficiency. Standard Cas9 is large and often requires complex delivery methods. Mammoth’s Cas14 and CasΦ are ultracompact, allowing them to fit into a single AAV vector, which simplifies the treatment process and potentially increases safety.

When will Mammoth Biosciences go public?

There is no official date for a Mammoth Biosciences IPO. Most analysts believe the company will wait for initial clinical data from its MB-111 program or a more favorable biotech market before listing on the Nasdaq or NYSE.

Does Mammoth Biosciences still do COVID-19 testing?

No, the company strategically pivoted away from diagnostics in 2023 to focus entirely on therapeutics. While their DETECTR technology remains a part of their IP portfolio, it is no longer the primary focus of their R&D efforts.